Compare VCEL & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCEL | BHVN |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1996 | 2022 |
| Metric | VCEL | BHVN |
|---|---|---|
| Price | $33.54 | $9.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $58.50 | $27.69 |
| AVG Volume (30 Days) | 423.1K | ★ 1.8M |
| Earning Date | 05-18-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | 26.08 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $276,259,000.00 | N/A |
| Revenue This Year | $19.09 | N/A |
| Revenue Next Year | $17.96 | N/A |
| P/E Ratio | $105.00 | ★ N/A |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $29.24 | $7.48 |
| 52 Week High | $49.10 | $31.18 |
| Indicator | VCEL | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 35.65 |
| Support Level | $29.59 | $9.32 |
| Resistance Level | $38.48 | $10.28 |
| Average True Range (ATR) | 1.47 | 0.64 |
| MACD | -0.36 | -0.18 |
| Stochastic Oscillator | 9.47 | 16.08 |
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.